Copenhagen-based medtech startup CathVision has successfully raised $9 million in its latest funding round from investors. The startup specializes in developing cutting-edge electrophysiology solutions, such as the ECGenius System and AI-powered analytic modules, to enhance clinical decision-making in the EP lab. Their primary focus is to improve the diagnosis and treatment of heart rhythm disorders. The newly acquired funds will be put towards advancing commercial operations, promoting wider adoption of the ECGenius System, expanding their sales team and presence in the United States, and supporting the continuous development of the CARDIALYTICS suite of AI-powered analytics. These analytics are designed to provide electrophysiologists with unparalleled levels of automated analysis during cardiac ablation procedures.
CathVision is a medical technology company that develops electrophysiology solutions centered around an innovative EP recording system and AI algorithm platform – the ECGenius System. Committed to empowering physicians to make more informed clinical decisions in the EP lab, CathVision is redefining the necessity of exceptional cardiac electrical signals to diagnose, characterize, and treat the most common heart rhythm disorders. CathVision was founded in 2013 and is headquartered in Denmark with a U.S. office in Minnesota.
“Despite challenging times in the financial markets, CathVision remains a confident investment for stakeholders because we are achieving critical milestones that validate the need for our technology, revenue generation through successful commercialization, and our commitment to ongoing R&D,” said Mads Matthiesen, CEO, CathVision. “This investment round will support the acceleration of commercial adoption through 2024 as we position CathVision to significantly impact how, throughout the United States, we help physicians treat cardiac arrhythmias more effectively.”
The ECGenius System includes a proprietary hardware amplifier capable of acquiring high-fidelity, low-noise cardiac electrograms. The technology represents a crucial progression in the quality of cardiac signal acquisition, the accuracy of electrogram interpretation, and the advancement of therapy support to help electrophysiologists improve the overall diagnosis and treatment of complex atrial arrhythmias, including atrial fibrillation (AF), which increases the risk of stroke and heart failure.
Click to read more funding news.
